Abstract
Background. A third wave of COVID-19 infection is now sweeping across the globe. Severe injury of the epithelial barrier, caused by the action of respiratory viruses (including coronaviruses), facilitates the invasion of the respiratory tract with other germs, like viruses, fungy or bscteria. Methods. 92 inpatients with COVID-19 pneumonia and 68 inpatients with nosocomial pneumonia (NP) non COVID-19 were enrolled in our study. For microbiological assessment sputum samples were collected. Statistical analysis performed using the x2 test (Statistica software, version 7.0). Results. From the 92 COVID-19 patients 64 (69,2%) were dignosed with secondary nosocomial bacterial infection (SNBI). Overall ESKAPE agents, like K.pneumoniae, E.faecium, Acinetobacter spp. and Ps.aeruginosa were highly detected in SARS- CoV-2 group — 85,7%. in opposed to non COVID-19 group, bacterial agents isolated from the patients with SARS-CoV-2 SNBI manifested higher rate of antibiotical panresistance (p < 0,05). Conclusions. The study showed some etiological and antibiotic resistance differences of COVID-19 SNBI, compared to non SARS-CoV-2 NP and a higher rate of antibiotical panresistance in COVID-19 group. Thus, the empirical treatment in bacterial co-infections in SARS-CoV-2 patients requires proven argumentation and adjustment to antibiotic resistance data in each case separately.
Highlights
A third wave of COVID-19 infection is sweeping across the globe
92 inpatients with COVID-19 pneumonia and 68 inpatients with nosocomial pneumonia (NP) non COVID-19 were enrolled in our study
Overall ESKAPE agents, like K.pneumoniae, E.faecium, Acinetobacter spp. and Ps.aeruginosa were highly detected in SARSCoV-2 group – 85,7%. in opposed to non COVID-19 group, bacterial agents isolated from the patients with SARS-CoV-2 secondary nosocomial bacterial infection (SNBI) manifested higher rate of antibiotical panresistance (p 0,05)
Summary
Antibioticele s-au prescris la toți pacienții cu formă medie și gravă din primele zile ale internării pe o durată de 8-12 zile (94,5% bolnavi);. 2. Liu C., Wen Y., Wan W. et al Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin. CO-INFECŢIILE BACTERIENE PULMONARE ŞI ANTIBIOTICOREZISTENŢA ÎN SARS-COV-2: COALESCENŢA SUMBRĂ A LUMII POST-COVID-19. Din lotul de 92 pacienţi internaţi cu SARS-CoV-2 69,5% (64/92) pacienţi au fost eligibili pentru criteriul de infecție bacteriană secundară (IBS) pulmonară intraspitalicească. În total au fost analizate 84 culturi bacteriene, dintre care germenilor din grupul ESKAPE le-a revenit o pondere mai mare – 72 tulpini (85,7%). Studiul a evidenţiat unele diferenţe etiologice şi de antibiorezistenţă ale infecţiilor bacteriene secundare pulmonare în SARS-CoV-2, comparativ cu pneumoniile nosocomiale non COVID-19. Pulmonary bacterial co-infections and antibiotical resistance in SARS-COV-2: the dark coalescence of post-covid-19 world
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Bulletin of the Academy of Sciences of Moldova. Medical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
